- Home
- INTR vs VKTX Comparison
INTR vs VKTX Comparison
Compare INTR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | VKTX |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INTR | VKTX |
|---|---|---|
| Price | $8.18 | $33.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $8.00 | ★ $88.00 |
| AVG Volume (30 Days) | ★ 3.2M | 2.6M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $87.92 | N/A |
| Revenue Next Year | $18.69 | N/A |
| P/E Ratio | $16.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $18.92 |
| 52 Week High | $10.36 | $43.15 |
Technical Indicators
Market Signals| Indicator | INTR | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 56.10 |
| Support Level | $7.94 | $30.73 |
| Resistance Level | $8.53 | $35.66 |
| Average True Range (ATR) | 0.37 | 1.59 |
| MACD | -0.09 | 0.20 |
| Stochastic Oscillator | 21.93 | 65.24 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.